Aventis Sees “Blurring” Of Rx/OTC Distinctions; Change Coming For Allegra?
Executive Summary
The antihistamine market can no longer comfortably be divided between prescription and OTC entrants, Aventis Chief Operating Officer Richard Markham suggested during the J.P. Morgan health care conference in San Francisco Jan. 13
You may also be interested in...
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid
Schering Sales Force Recruitment Is 80% Complete; Morale Remains High
Recruitment for Schering-Plough's sales force expansion is 80% complete, Global Pharmaceutical President Carrie Cox told investors during a year-end conference call Jan. 26